Topics

TKI Discontinuation Safe in CML, But Patient Selection Is Key

10:35 EDT 1 May 2019 | OncLive

Although TKIs have significantly improved life expectancy for patients with chronic myeloid leukemia, investigators are actively examining ways to safely discontinue treatment without sacrificing benefit.

Original Article: TKI Discontinuation Safe in CML, But Patient Selection Is Key

NEXT ARTICLE

More From BioPortfolio on "TKI Discontinuation Safe in CML, But Patient Selection Is Key"

Quick Search